Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The current work is on the compound potency that is most effective via the delivery system. Human trials are tricky because our systems handle elements and compounds at varying rates.
You will know the answer once the pharma news breaks. Mid May will give the early numbers that really matter as to the support level. The PPS then will depend on the clinical trials. Right now $1 should be an easy goal.
Walgreen's ads will soon tell the story to the masses-something these threads cannot do. Company wants their products on display before they break the news. And it will not stop with Walgreens.
Stricker, Woods, Furyk, Westwood & Mickelson... 275
Walgreens is stocking their shelves with all three products. Why someone in the know would hesitate to release this info is comical. More contracts in the works.
Every golf pro shop I've been in has energy booster drinks. I just checked on why Tiger is not pushing Enerjel. There is a conflict of interest-but he is promoting Electrofuse & Powerfuse. The suggested markup for their products is 100% but GNC is higher by ~~40%. Why, I don't know.
No! Come fall when they sign with a pharma they will decide on a R/S .
DROP-news that is just the start of Shark Tank's new PR program.
http://ir.stockpr.com/fusescience/company-news/detail/874
Fear not oh wise one. They chatter-we bought, buy and hold. Winners come from the stout, the experienced and the smart. ;)
Carlos at distribution says they are swamped with orders. Company official saying they are much aware of pps drop. Company also will not decide what compounds/ingredients will be used by pharma. Just the delivery methods.
Capital gains-hold for a year and tax break is huge.
Energel works,the other two don't offer the "jolt" kids or modern man enjoys or seeks. These 3 products will not be the driving force to move the pps to the levels above $1. The company is doing the right thing by not putting out news-just to satisfy the folly of d-traders.
Dropping into the low $8-gold is not going higher unless we enter a war.
If this company were a p&d, as some suggest, then pr's would flow on a weekly basis. There was a mention that the shareholders on record was 80. This too is false, no matter what the filings state. The number of shareholders is over 5,000. Don't believe me? Then do some real dd and you will be surprised. The next Q will be released next month and it will tell the real story, not the false "facts???' posted on this or other useless threads.
Invest anywhere in the sub 50 cent range, sit back and watch for the income. LT CGs is the ONLY way to play the OTC.
2013 Masters Invitees
Bjorn, Thomas
Bradley, Keegan
Cabrera, Angel
Choi, K.J.
Cink, Stewart
Clark, Tim
Clarke, Darren
Coetzee, George
Colsaerts, Nicolas
Couples, Fred
Crenshaw, Ben
Curtis, Ben
Day, Jason
Donald, Luke
Donaldson, Jamie
Dufner, Jason
Dunbar, Alan
Els, Ernie
Fernandez-Castano, Gonzalo
Fowler, Rickie
Fox, Steven
Fujita, Hiroyuki
Furyk, Jim
Garcia, Sergio
Garrigus, Robert
Gay, Brian
Glover, Lucas
Grace, Branden
Guan, Tianlang
Haas, Bill
Hanson, Peter
Harrington, Padraig
Henley, Russell
Huh, John
Immelman, Trevor
Ishikawa, Ryo
Jacobson, Fredrik
Johnson, Dustin
Johnson, Zach
Kaymer, Martin
Kuchar, Matt
Langer, Bernhard
Lawrie, Paul
Leishman, Marc
Lyle, Sandy
Lynn, David
Mahan, Hunter
Manassero, Matteo
McDowell, Graeme
McIlroy, Rory
Merrick, John
Mickelson, Phil
Mize, Larry
Molinari, Francesco
Moore, Ryan
Na, Kevin
O'Meara, Mark
Olazabal, Jose-Maria
Olesen, Thorbjorn
Oosthuizen, Louis
Peterson, John
Pettersson, Carl
Piercy, Scott
Points, D.A.
Potter Jr, Ted
Poulter, Ian
Rose, Justin
Schwartzel, Charl
Scott, Adam
Senden, John
Simpson, Webb
Singh, Vijay
Smith, Nathan
Snedeker, Brandt
Stadler, Craig
Stenson, Henrik
Sterne, Richard
Streelman, Kevin
Stricker, Steve
Thompson, Michael
Toms, David
Van Pelt, Bo
Vogel, T.J.
Watney, Nick
Watson, Bubba
Watson, Tom
Weaver, Michael
Weir, Mike
Westwood, Lee
Wiratchant, Thaworn
Woods, Tiger
Woosnam, Ian
Yang, Yong-Eun
DROP reports like these will only help the bottom line and make these products a household name
http://www.seanmrivers.com/2013/03/07/product-review-fuse-science/
TEJS just moved ask to 0.195 which is very positive.
Smart money would agree.
6.1mm shares short-watch for a huge pps move higher as shorts cover. ;)
Not surprised-CY is top shelf and TJ says pps is valued at $22.00.
Definition
A stock split which reduces the number of outstanding shares and increases the per-share price proportionately. This is usually an attempt by a company to disguise a falling stock price, since the actual market capitalization of the stock does not change at all. For example, if a company declares a one-for-ten reverse split, then a person who previously held 20 shares valued by the market at $1 each will then have 2 shares worth $10 each. Many stock exchanges in the U.S. do not allow companies with a stock price of less than $1 to remain listed, and many such companies then have to undertake reverse splits if they want to remain listed.
You really still don't get it. FUSE is looking to SELL its patents and not be a retailer of products. Pharma deal and all this chatter of sales,TA, PR's, Tiger, distributors etc go out the window. PPS will blow by $2+ in minutes once they cement this deal, now in the works.
Geez you are SO sharp. You don't get funders without supporting them via PR's or locking insider holdings.
The slight selling panic after the 8k release shows the lack of smarts by the average investor. Tiger's management team examined the filing before release so until his involvement is reduced or removed, no sense taking any creedance in daily flucuations.
DROP-moving again on this news.
Fuse Science, Inc. Ramps Up to Support High Demand
6 minutes ago - PR Newswire via Comtex
Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals announced the implementation of initiatives to support execution of its national roll-out strategy for PowerFuse(TM), ElectroFuse(TM) and EnerJel(TM).
"Since our partnership with Daymond John and the Shark Branding team, there has been a marked acceleration of the business," stated Brian Tuffin, CEO Fuse Science. "Our strategy is very specific and focused on the national expansion of our product portfolio and advancement of licensing opportunities for our proprietary technology. An investment is being made to expand production capacity of our DROP technology products comparable to that undertaken last summer for the EnerJel(TM) brand. This will allow for the production of millions of units of our PowerFuse(TM) and ElectroFuse(TM) products to support the pipeline we expect to develop through our planned national retail partnerships, which we anticipate announcing in the near future. Our goal is to have our DROP products in 10,000 retail locations by the end of the third calendar quarter of 2013 and in over 15,000 retail locations by the end of the fourth quarter. A portion of the proceeds from our recently announced capital infusion will be used to fund this strategy. We believe that the national rollout strategy will afford us the opportunity to achieve significant revenue growth.
"Management fully understands the ongoing need for capital to facilitate growth in an accelerated environment. Given the reported margin strength of the Company, there is a systemic focus in becoming cash flow positive ahead in the near term, which we believe will set forth the stage for self-sustainability," added Tuffin.
About Fuse Science, Inc. Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).
I do not think Walmart is going to be a distributor.
The financers made their money as did the group that put together the funding. Nothing new.
DROP-the Bloomberg interview has begun to alert the public to a 10x bagger in the coming months or sooner. ;))
This might interest the believers:
https://twitter.com/search?q=$DROP&src=ctag
DROP-todays move higher is just the beginning.
I think they have an e-mail elert system so once they restock they will notify. The willow bark is the active pain relief ingredient and it has been used in far east for hundreds of years. Transderminal lets it work quickly and without the side effects if ingested via the mouth.
Free shipping on over $100.00 orders-so if you need other products from Lucky, you can save. I'm not pushing this outfit but the prices are competitive.
DROP-if this company signs with a pharma, as this video from Bloomberg suggests, then 10x is easy.
http://www.bloomberg.com/video/daymond-john-s-world-from-fashion-to-science-dQO5TyiPTDmvAKskFBquMQ.html
Barbara says if ES gets funding she will reco re-entering shell.
Shark Branding Corp. CEO Daymond John and Fuse Science CEO Brian Tuffin to be interviewed on Bloomberg Television's "Taking Stock with Pimm Fox"
MIAMI LAKES, Fla., March 1, 2013 /PRNewswire via COMTEX/ -- Fuse Science, Inc. (OTCQB: DROP), (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals is pleased to announce that CEO Brian Tuffin and Daymond John, CEO of Shark Branding, LLC and Shark Branding Corp. are scheduled to be interviewed on Bloomberg Television's "Taking Stock with Pimm Fox" today, March 1st, 2013.
"Taking Stock", hosted by Bloomberg Television anchor Pimm Fox, offers insight into company news, long-term strategy, trading tactics, market techniques, stocks, bonds, commodities and currencies and is broadcast weekdays at 5:00 pm EST.
A replay of the interview will be archived and available within the Investor Relations section of the Fuse Science, Inc. corporate web site: http://ir.stockpr.com/fusescience/overview shortly after the broadcast.
About Shark Branding Corp.
Shark Branding's team of expert communicators, strategic analysts, and creative heavyweights excels in transforming businesses into iconic brands. At the helm is business and branding expert Daymond John, CEO and Founder of FUBU, a $6 billion global fashion game-changer. Daymond's entrepreneurialism and trend-moving influence are key to the company's cultivation of great brands. Putting products in the hands of influencers and trendsetters is Shark Branding's core practice. Shark Branding clients benefit from a 360 degree approach to the growth of a healthy, successful brand with services ranging from brand strategy, design, and licensing; event development; celebrity affiliation and media; digital marketing; and the fundamentals of business leadership. For more information, visit: www.sharkbranding.com
About Fuse Science, Inc.
Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).
For Fuse news as it happens, follow @Fuse_Science on Twitter and Like Us on Facebook HERE!
For more information: To schedule an interview:
Fuse Science, Inc. Gus DeQuesada
Investor Relations Michelsen Advertising
Direct: (305) 503-3873, Ext. 2 C-305-733-1410 / 786-488-7138
Email: ir@fusescience.com prnews@michelsenadvertising.com